Reversal of lung cancer multidrug resistance by pH-responsive micelleplexes mediating co-delivery of siRNA and paclitaxel.
Identifieur interne : 001007 ( Main/Exploration ); précédent : 001006; suivant : 001008Reversal of lung cancer multidrug resistance by pH-responsive micelleplexes mediating co-delivery of siRNA and paclitaxel.
Auteurs : Haijun Yu [République populaire de Chine] ; Zhiai Xu ; Xianzhi Chen ; Leilei Xu ; Qi Yin ; Zhiwen Zhang ; Yaping LiSource :
- Macromolecular bioscience [ 1616-5195 ] ; 2014.
Descripteurs français
- KwdFr :
- Antinéoplasiques d'origine végétale (administration et posologie), Antinéoplasiques d'origine végétale (pharmacologie), Apoptose (), Apoptose (génétique), Chloroquine (pharmacologie), Concentration en ions d'hydrogène, Humains, Lignée cellulaire tumorale, Luciferases (génétique), Macrolides (pharmacologie), Micelles, Multirésistance aux médicaments (), Multirésistance aux médicaments (génétique), Nanoparticules (), Nanoparticules (administration et posologie), Paclitaxel (administration et posologie), Paclitaxel (pharmacologie), Petit ARN interférent (administration et posologie), Petit ARN interférent (génétique), Poly(acides méthacryliques), Protéines proto-oncogènes c-bcl-2 (génétique), Résistance aux médicaments antinéoplasiques (), Résistance aux médicaments antinéoplasiques (génétique), Techniques de knock-down de gènes, Transfection, Tumeurs du poumon (anatomopathologie), Tumeurs du poumon (génétique), Tumeurs du poumon (traitement médicamenteux), Vecteurs de médicaments.
- MESH :
- administration et posologie : Antinéoplasiques d'origine végétale, Nanoparticules, Paclitaxel, Petit ARN interférent.
- anatomopathologie : Tumeurs du poumon.
- génétique : Apoptose, Luciferases, Multirésistance aux médicaments, Petit ARN interférent, Protéines proto-oncogènes c-bcl-2, Résistance aux médicaments antinéoplasiques, Tumeurs du poumon.
- pharmacologie : Antinéoplasiques d'origine végétale, Chloroquine, Macrolides, Paclitaxel.
- traitement médicamenteux : Tumeurs du poumon.
- Apoptose, Concentration en ions d'hydrogène, Humains, Lignée cellulaire tumorale, Micelles, Multirésistance aux médicaments, Nanoparticules, Poly(acides méthacryliques), Résistance aux médicaments antinéoplasiques, Techniques de knock-down de gènes, Transfection, Vecteurs de médicaments.
English descriptors
- KwdEn :
- Antineoplastic Agents, Phytogenic (administration & dosage), Antineoplastic Agents, Phytogenic (pharmacology), Apoptosis (drug effects), Apoptosis (genetics), Cell Line, Tumor, Chloroquine (pharmacology), Drug Carriers, Drug Resistance, Multiple (drug effects), Drug Resistance, Multiple (genetics), Drug Resistance, Neoplasm (drug effects), Drug Resistance, Neoplasm (genetics), Gene Knockdown Techniques, Humans, Hydrogen-Ion Concentration, Luciferases (genetics), Lung Neoplasms (drug therapy), Lung Neoplasms (genetics), Lung Neoplasms (pathology), Macrolides (pharmacology), Micelles, Nanoparticles (administration & dosage), Nanoparticles (chemistry), Paclitaxel (administration & dosage), Paclitaxel (pharmacology), Polymethacrylic Acids, Proto-Oncogene Proteins c-bcl-2 (genetics), RNA, Small Interfering (administration & dosage), RNA, Small Interfering (genetics), Transfection.
- MESH :
- chemical , administration & dosage : Antineoplastic Agents, Phytogenic, Paclitaxel, RNA, Small Interfering.
- chemical , genetics : Luciferases, Proto-Oncogene Proteins c-bcl-2, RNA, Small Interfering.
- chemical , pharmacology : Antineoplastic Agents, Phytogenic, Chloroquine, Macrolides, Paclitaxel.
- administration & dosage : Nanoparticles.
- chemistry : Nanoparticles.
- drug effects : Apoptosis, Drug Resistance, Multiple, Drug Resistance, Neoplasm.
- drug therapy : Lung Neoplasms.
- genetics : Apoptosis, Drug Resistance, Multiple, Drug Resistance, Neoplasm, Lung Neoplasms.
- pathology : Lung Neoplasms.
- Cell Line, Tumor, Drug Carriers, Gene Knockdown Techniques, Humans, Hydrogen-Ion Concentration, Micelles, Polymethacrylic Acids, Transfection.
Abstract
The recent advances in RNA interference (RNAi) technology provided novel and promising solutions for human cancer treatment. In this study, the application of dual pH-responsive cationic micellar nanoparticles for small interfering RNA (siRNA) and paclitaxel (PTX) co-delivery to overcome cancer multidrug resistance (MDR) is reported. The in vitro siRNA transfection shows that siRNA-luciferase (Luc) loaded micelleplexes efficiently silences Luc expression in various carcinoma cell lines. The Luc knockdown ability of the micelleplexes can be enhanced by choloquine (CQ) co-incubation. However, is abolished by bafilomycin-A1 (Baf-A1) treatment. The micelleplexes are further exploited for co-delivery of siRNA-Bcl-2 and PTX to Bcl-2 overexpressing A549 lung cancer cells (A549-Bcl-2). The experimental results show that the micelleplexes could sensitize A549-Bcl-2 cells to PTX via down-regulation of anti-apoptosis gene of Bcl-2, suggesting that PDMA-b-PDPA micelleplexes are promising nanovectors for siRNA and anti-cancer drug co-delivery to overcome cancer MDR.
DOI: 10.1002/mabi.201300282
PubMed: 23966347
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000328
- to stream PubMed, to step Curation: 000328
- to stream PubMed, to step Checkpoint: 000275
- to stream Ncbi, to step Merge: 000211
- to stream Ncbi, to step Curation: 000211
- to stream Ncbi, to step Checkpoint: 000211
- to stream Main, to step Merge: 001008
- to stream Main, to step Curation: 001007
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Reversal of lung cancer multidrug resistance by pH-responsive micelleplexes mediating co-delivery of siRNA and paclitaxel.</title><author><name sortKey="Yu, Haijun" sort="Yu, Haijun" uniqKey="Yu H" first="Haijun" last="Yu">Haijun Yu</name><affiliation wicri:level="1"><nlm:affiliation>Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Shanghai, 201203, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Shanghai, 201203</wicri:regionArea><wicri:noRegion>201203</wicri:noRegion></affiliation></author><author><name sortKey="Xu, Zhiai" sort="Xu, Zhiai" uniqKey="Xu Z" first="Zhiai" last="Xu">Zhiai Xu</name></author><author><name sortKey="Chen, Xianzhi" sort="Chen, Xianzhi" uniqKey="Chen X" first="Xianzhi" last="Chen">Xianzhi Chen</name></author><author><name sortKey="Xu, Leilei" sort="Xu, Leilei" uniqKey="Xu L" first="Leilei" last="Xu">Leilei Xu</name></author><author><name sortKey="Yin, Qi" sort="Yin, Qi" uniqKey="Yin Q" first="Qi" last="Yin">Qi Yin</name></author><author><name sortKey="Zhang, Zhiwen" sort="Zhang, Zhiwen" uniqKey="Zhang Z" first="Zhiwen" last="Zhang">Zhiwen Zhang</name></author><author><name sortKey="Li, Yaping" sort="Li, Yaping" uniqKey="Li Y" first="Yaping" last="Li">Yaping Li</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:23966347</idno><idno type="pmid">23966347</idno><idno type="doi">10.1002/mabi.201300282</idno><idno type="wicri:Area/PubMed/Corpus">000328</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000328</idno><idno type="wicri:Area/PubMed/Curation">000328</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000328</idno><idno type="wicri:Area/PubMed/Checkpoint">000275</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000275</idno><idno type="wicri:Area/Ncbi/Merge">000211</idno><idno type="wicri:Area/Ncbi/Curation">000211</idno><idno type="wicri:Area/Ncbi/Checkpoint">000211</idno><idno type="wicri:Area/Main/Merge">001008</idno><idno type="wicri:Area/Main/Curation">001007</idno><idno type="wicri:Area/Main/Exploration">001007</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Reversal of lung cancer multidrug resistance by pH-responsive micelleplexes mediating co-delivery of siRNA and paclitaxel.</title><author><name sortKey="Yu, Haijun" sort="Yu, Haijun" uniqKey="Yu H" first="Haijun" last="Yu">Haijun Yu</name><affiliation wicri:level="1"><nlm:affiliation>Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Shanghai, 201203, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Shanghai, 201203</wicri:regionArea><wicri:noRegion>201203</wicri:noRegion></affiliation></author><author><name sortKey="Xu, Zhiai" sort="Xu, Zhiai" uniqKey="Xu Z" first="Zhiai" last="Xu">Zhiai Xu</name></author><author><name sortKey="Chen, Xianzhi" sort="Chen, Xianzhi" uniqKey="Chen X" first="Xianzhi" last="Chen">Xianzhi Chen</name></author><author><name sortKey="Xu, Leilei" sort="Xu, Leilei" uniqKey="Xu L" first="Leilei" last="Xu">Leilei Xu</name></author><author><name sortKey="Yin, Qi" sort="Yin, Qi" uniqKey="Yin Q" first="Qi" last="Yin">Qi Yin</name></author><author><name sortKey="Zhang, Zhiwen" sort="Zhang, Zhiwen" uniqKey="Zhang Z" first="Zhiwen" last="Zhang">Zhiwen Zhang</name></author><author><name sortKey="Li, Yaping" sort="Li, Yaping" uniqKey="Li Y" first="Yaping" last="Li">Yaping Li</name></author></analytic><series><title level="j">Macromolecular bioscience</title><idno type="eISSN">1616-5195</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic Agents, Phytogenic (administration & dosage)</term><term>Antineoplastic Agents, Phytogenic (pharmacology)</term><term>Apoptosis (drug effects)</term><term>Apoptosis (genetics)</term><term>Cell Line, Tumor</term><term>Chloroquine (pharmacology)</term><term>Drug Carriers</term><term>Drug Resistance, Multiple (drug effects)</term><term>Drug Resistance, Multiple (genetics)</term><term>Drug Resistance, Neoplasm (drug effects)</term><term>Drug Resistance, Neoplasm (genetics)</term><term>Gene Knockdown Techniques</term><term>Humans</term><term>Hydrogen-Ion Concentration</term><term>Luciferases (genetics)</term><term>Lung Neoplasms (drug therapy)</term><term>Lung Neoplasms (genetics)</term><term>Lung Neoplasms (pathology)</term><term>Macrolides (pharmacology)</term><term>Micelles</term><term>Nanoparticles (administration & dosage)</term><term>Nanoparticles (chemistry)</term><term>Paclitaxel (administration & dosage)</term><term>Paclitaxel (pharmacology)</term><term>Polymethacrylic Acids</term><term>Proto-Oncogene Proteins c-bcl-2 (genetics)</term><term>RNA, Small Interfering (administration & dosage)</term><term>RNA, Small Interfering (genetics)</term><term>Transfection</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antinéoplasiques d'origine végétale (administration et posologie)</term><term>Antinéoplasiques d'origine végétale (pharmacologie)</term><term>Apoptose ()</term><term>Apoptose (génétique)</term><term>Chloroquine (pharmacologie)</term><term>Concentration en ions d'hydrogène</term><term>Humains</term><term>Lignée cellulaire tumorale</term><term>Luciferases (génétique)</term><term>Macrolides (pharmacologie)</term><term>Micelles</term><term>Multirésistance aux médicaments ()</term><term>Multirésistance aux médicaments (génétique)</term><term>Nanoparticules ()</term><term>Nanoparticules (administration et posologie)</term><term>Paclitaxel (administration et posologie)</term><term>Paclitaxel (pharmacologie)</term><term>Petit ARN interférent (administration et posologie)</term><term>Petit ARN interférent (génétique)</term><term>Poly(acides méthacryliques)</term><term>Protéines proto-oncogènes c-bcl-2 (génétique)</term><term>Résistance aux médicaments antinéoplasiques ()</term><term>Résistance aux médicaments antinéoplasiques (génétique)</term><term>Techniques de knock-down de gènes</term><term>Transfection</term><term>Tumeurs du poumon (anatomopathologie)</term><term>Tumeurs du poumon (génétique)</term><term>Tumeurs du poumon (traitement médicamenteux)</term><term>Vecteurs de médicaments</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antineoplastic Agents, Phytogenic</term><term>Paclitaxel</term><term>RNA, Small Interfering</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Luciferases</term><term>Proto-Oncogene Proteins c-bcl-2</term><term>RNA, Small Interfering</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antineoplastic Agents, Phytogenic</term><term>Chloroquine</term><term>Macrolides</term><term>Paclitaxel</term></keywords><keywords scheme="MESH" qualifier="administration & dosage" xml:lang="en"><term>Nanoparticles</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antinéoplasiques d'origine végétale</term><term>Nanoparticules</term><term>Paclitaxel</term><term>Petit ARN interférent</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Tumeurs du poumon</term></keywords><keywords scheme="MESH" qualifier="chemistry" xml:lang="en"><term>Nanoparticles</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Apoptosis</term><term>Drug Resistance, Multiple</term><term>Drug Resistance, Neoplasm</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Lung Neoplasms</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Apoptosis</term><term>Drug Resistance, Multiple</term><term>Drug Resistance, Neoplasm</term><term>Lung Neoplasms</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Apoptose</term><term>Luciferases</term><term>Multirésistance aux médicaments</term><term>Petit ARN interférent</term><term>Protéines proto-oncogènes c-bcl-2</term><term>Résistance aux médicaments antinéoplasiques</term><term>Tumeurs du poumon</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Lung Neoplasms</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antinéoplasiques d'origine végétale</term><term>Chloroquine</term><term>Macrolides</term><term>Paclitaxel</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tumeurs du poumon</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Cell Line, Tumor</term><term>Drug Carriers</term><term>Gene Knockdown Techniques</term><term>Humans</term><term>Hydrogen-Ion Concentration</term><term>Micelles</term><term>Polymethacrylic Acids</term><term>Transfection</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Apoptose</term><term>Concentration en ions d'hydrogène</term><term>Humains</term><term>Lignée cellulaire tumorale</term><term>Micelles</term><term>Multirésistance aux médicaments</term><term>Nanoparticules</term><term>Poly(acides méthacryliques)</term><term>Résistance aux médicaments antinéoplasiques</term><term>Techniques de knock-down de gènes</term><term>Transfection</term><term>Vecteurs de médicaments</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The recent advances in RNA interference (RNAi) technology provided novel and promising solutions for human cancer treatment. In this study, the application of dual pH-responsive cationic micellar nanoparticles for small interfering RNA (siRNA) and paclitaxel (PTX) co-delivery to overcome cancer multidrug resistance (MDR) is reported. The in vitro siRNA transfection shows that siRNA-luciferase (Luc) loaded micelleplexes efficiently silences Luc expression in various carcinoma cell lines. The Luc knockdown ability of the micelleplexes can be enhanced by choloquine (CQ) co-incubation. However, is abolished by bafilomycin-A1 (Baf-A1) treatment. The micelleplexes are further exploited for co-delivery of siRNA-Bcl-2 and PTX to Bcl-2 overexpressing A549 lung cancer cells (A549-Bcl-2). The experimental results show that the micelleplexes could sensitize A549-Bcl-2 cells to PTX via down-regulation of anti-apoptosis gene of Bcl-2, suggesting that PDMA-b-PDPA micelleplexes are promising nanovectors for siRNA and anti-cancer drug co-delivery to overcome cancer MDR. </div></front></TEI><affiliations><list><country><li>République populaire de Chine</li></country></list><tree><noCountry><name sortKey="Chen, Xianzhi" sort="Chen, Xianzhi" uniqKey="Chen X" first="Xianzhi" last="Chen">Xianzhi Chen</name><name sortKey="Li, Yaping" sort="Li, Yaping" uniqKey="Li Y" first="Yaping" last="Li">Yaping Li</name><name sortKey="Xu, Leilei" sort="Xu, Leilei" uniqKey="Xu L" first="Leilei" last="Xu">Leilei Xu</name><name sortKey="Xu, Zhiai" sort="Xu, Zhiai" uniqKey="Xu Z" first="Zhiai" last="Xu">Zhiai Xu</name><name sortKey="Yin, Qi" sort="Yin, Qi" uniqKey="Yin Q" first="Qi" last="Yin">Qi Yin</name><name sortKey="Zhang, Zhiwen" sort="Zhang, Zhiwen" uniqKey="Zhang Z" first="Zhiwen" last="Zhang">Zhiwen Zhang</name></noCountry><country name="République populaire de Chine"><noRegion><name sortKey="Yu, Haijun" sort="Yu, Haijun" uniqKey="Yu H" first="Haijun" last="Yu">Haijun Yu</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001007 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001007 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:23966347
|texte= Reversal of lung cancer multidrug resistance by pH-responsive micelleplexes mediating co-delivery of siRNA and paclitaxel.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:23966347" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a ChloroquineV1
| This area was generated with Dilib version V0.6.33. |  |